Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments
To date, 10 clinical trial sites have been initiated in the Phase 1b trial evaluating ATRC-101 in multiple solid tumor cancers.
- To date, 10 clinical trial sites have been initiated in the Phase 1b trial evaluating ATRC-101 in multiple solid tumor cancers.
- Three patients have been enrolled in the fourth dose cohort (10mg/kg) of the dose escalation portion of the trial.
- Research and development expenses for the year ended December 31, 2020 were $62.0 million, including non-cash share-based compensation expense of $5.9 million.
- General and administrative expenses for the year ended December 31, 2020 were $26.8 million, including non-cash share-based compensation expense of $6.6 million.